Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
1878-A INDIVIDUALIZED HCV TREATMENT FOR PWIDS ON OPIOID AGONIST THERAPY LED TO EXCELLENT ADHERENCE THROUGHOUT THE COVID19 PANDEMIC Caroline Schwarz 1,2 , Angelika Schtz 3 , Raphael Schubert 3 , Michael Schwarz 2 , Anika Jenke 3 , David Josef Maria Bauer 1,2 , Lukas Burghart 1,2 , Benjamin Steinwender 3 , Enisa Gutic 1 , Thomas Reiberger 2,4 , Hans Haltmayer 3 and Michael Gschwantler 1,5 , (1)Klinik Ottakring, (2)Medical University of Vienna, (3)Suchthilfe Wien Ggmbh, (4)Cemm Research Center for Molecular Medicine of the Austrian Academy of Sciences, (5)Sigmund Freud University Background: Directly observed therapy (DOT) with DAAs (direct-acting antivirals) is successful in eliminating HCV in PWIDs (people who inject drugs) on opioid agonist therapy (OAT): DAAs are prescribed via a low-threshold facility (LTF), and supervised DAA administration alongside OAT is performed at a pharmacy or LTF
GLP-1 and GIP Weight Loss Injections GLP-1 and GIP weight loss injections have become increasingly popular among patients looking for provider-supervised medical weight loss programs
The scale may not change noticeably until day 1014 even though the medication is actively suppressing appetite
Given that atherosclerotic cardiovascular disease and CKD are the leading causes of morbidity and mortality in type 1 diabetes [24], it is reassuring that we show that SGLT2i therapy also confers similar benefits in type 1 diabetes
